Herantis Pharma PLC · OMXHEX:HRTIS
Herantis Pharma — IPO Roadshow (May 2014)
17 slides from Herantis Pharma's IPO roadshow presentation, May 12, 2014
Slide 1: Herantis – new pharmaceutical company
Herantis – new pharmaceutical company Company overview and future prospects CEO Pekka Simula 12 May 2014 1 Copyright © 2014 HERANTIS PHARMA Plc. All rights reserved.
Slide 2: Disclaimer
Disclaimer • Hermo Pharma Ltd (”Company”) has prepared this presentation of the Company as background material only. This presentation is intended for use only with the formal prospectus approved by Finand’s Financial Supervisory Authority (Finanssivalvonta). • This presentation does not intend to p
Slide 3: Herantis Pharma Plc
Herantis Pharma Plc • Drug development company formed through Hermo Pharma Ltd’s acquisition of 99% of shares in Laurantis Pharma Ltd in Apr 2014 • Develops medicinal products especially for the treatment of inflammatory, CNS, and lymphatic diseases – Emphasis in areas of unmet clinical need • Exper
Slide 4: Herantis' background
Herantis’ background • Herantis formed in 2014 through the merger of two pharmaceutical companies, Hermo Pharma and Laurantis Pharma – Hermo Pharma’s development based on Academy Professor Mart Saarma’s scientific research – Laurantis Pharma’s drug candidates are based on research by e.g. Academy Pr
Slide 5: Board of directors and management
Board of directors and management Pekka Mattila" Jonathan Knowles" Timo Veromaa" Frans Wuite" James Phillips" Aki Prihti" MSc, Chairman, PhD, Board member, Ex- MD, PhD, Board MD, MBA, Board MD, MBA, Board MSc, Board member, CEO Desentum, Management team Roche, member, CEO Biotie member, CEO Oncos me
Slide 6: Introduction to clinical development
Introduction to clinical development Idea Medicine" 0-5 years" 3-5 years" 3-5 years" Preclinical stage" Early clinical development: Phase 1 Research and development and Phase 2 clinical studies" searching for and assessing Late stage clinical new drug candidates for safety Phase 1 and Phase 2 clinic
Slide 7: Herantis' strategy
Herantis’ strategy Herantis’ field of activity is pharmaceutical research and development in collaboration with its academic and commercial partners and: • Aiming at profitable growth in the long term: – Possible income from commercial partnership agreements is largely invested in new development pr
Slide 8: Herantis portfolio (drug candidates)
Herantis portfolio (drug candidates) Drug candidate Indication Preclin Phase 1 Phase 2 Phase 3 Launch Cis-UCA Eye Drops Dry Eye * CDNF growth Parkinson’s factor disease * Secondary Lymfactin lymphedema * Cis-UCA Atopic dermatitis** Emulsion Cream CDNF growth Amyotrofic lateral factor sclerosis (ALS)
Slide 9: Cis-UCA Eye Drops for dry eye
Cis-UCA Eye Drops for dry eye Based on preclinical and Phase 1 clinical results the Company believes that Cis-UCA Eye Drops have the potential of being the most efficacious and best tolerated prescription medicine in the treatment of dry eye. • Dry eye syndrome is the most common cause of irritation
Slide 10: CDNF for Parkinson's disease
CDNF for Parkinson’s disease Based on preclinical data the Company believes that CDNF is one of the most promising new compounds for the treatment of Parkinson’s disease. • Parkinson’s disease is a progressive neurodegenerative disease, which cannot be cured – Estimated seven million patients worldw
Slide 11: Lymfactin for secondary lymphedema
Lymfactin for secondary lymphedema Based on scientific studies Herantis believes that damage to lymphatic system leading to secondary lymphedema can be treated with Lymfactin. • Lymphedema is a chronic progressing disease with no approved medicines – Secondary lymphedema develops in estimated 15,000
Slide 12: Target development schedule
Target development schedule • Initial public offering and listing in NASDAQ OMX First North Helsinki 2014 • Cis-UCA Eye Drops: Phase 2 clinical study launched • Lymfactin Phase 1 clinical study launched • Cis-UCA Eye Drops: Phase 2 clinical study completed 2015 • CDNF / Parkinson’s disease: Phase 1
Slide 13: Risks
Risks* In addition to normal financial risks, risks related to securities, and other related risks there are essential risks related to Herantis and its business. • No commercial products – The Initial Public Offering in First North Helsinki aims to fund the Company to develop its three main product
Slide 14: Strengths
Strengths • Three drug candidates – Independent development programs, each individually with potential to reach a strong position in the global market for pharmaceutical products • Experienced team and international network of collaborators – International experience in each phase of drug developmen
Slide 15: Herantis IPO in First North Helsinki – HRTIS: Selected details
Herantis IPO in First North Helsinki – HRTIS: Selected details • Offering at most 1,600,000 new shares for 10.50 € per share – Approximately 37% of shares and votes in Herantis – Over-allotment option of at most additional 1.000.000 new shares, in which case the total amount is approximately 49% of
Slide 16: Main shareholders at the time of IPO
Main shareholders at the time of IPO* Shareholder # of % votes/ shares shares* Inveni Life Sciences Fund I Ky 614.271 22,8 % Helsingin yliopiston rahastot (Helsinki University Funds) 473.638 17,6 % Aloitusrahasto Vera Oy 449.660 16,7 % Mart Saarma 159.000 5,9 % Eero Castrén 155.000 5,8 % Heikki Rauv
Slide 17: Thank you!
Thank you! 12 May 2014 17 Copyright © 2014 HERANTIS PHARMA Plc. All rights reserved.